Is Bayesian analysis ready for use in phase III randomized clinical trials? Beware the sound of the sirens

Stroke

Volumn 36, Issue 7, 2005, Pages 1622-1623

  Howard, George ^a   Coffey, Christopher S ^a   Cutter, Gary R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Bayes theorem; Clinical trials; Probability

Indexed keywords

BAYES THEOREM; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SHORT SURVEY; STATISTICAL ANALYSIS; STROKE;

BAYES THEOREM; CLINICAL TRIALS, PHASE III; DATA INTERPRETATION, STATISTICAL; HUMANS; PROBABILITY; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 22044439979     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000170638.55491.bb     Document Type: Short Survey

References (6)

1. Diamond GA, Kaul S. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. J Am Coll Cardiol. 2004;43:1929-1939.
2. Spiegelhalter DJ, Freedma LS, Parmar MK. Applying Bayesian ideas in drug development and clinical trials. Stat Med. 1993;12:1501-1511.
3. Cui L, Hung HMJ, Wang S. Modification of sample size in group sequential clinical trials. Biometrics. 1999;55:853-857.
4. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics. 1999;55:1286-1290.
5. Muller H, Schafer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics. 2001;57:886-891.
6. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics. 1995;51:1315-1324.